France· FR:61561635
MARSILID 50 mg, comprimé sécable
A iproniazide product containing phosphate d'iproniazide, registered in France by EFISCIENS (MALTE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- PHOSPHATE D'IPRONIAZIDE
- Manufacturer
- EFISCIENS (MALTE)
- Country
- France (FR)
- ATC code
- N06AF05
- ATC class
- Iproniazide
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400936882508tube(s) polypropylène de 30 comprimé(s)EUR 115.2
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d7c68812-d4d5-410f-94a1-7d361dd49e89 GET /v1/drugs/d7c68812-d4d5-410f-94a1-7d361dd49e89?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "61561635",
"date_amm": "1991-12-02",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "PHOSPHATE D'IPRONIAZIDE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé sécable",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about iproniazide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.